All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Celltrion receives FDA approval for EYDENZELT aflibercept biosimilar targeting VEGF for diabetic macular edema
Protein therapy, ophthalmology, biosimilar, VEGF inhibitor, age-related macular degeneration, diabetic macular edema - Read more

THE GOOD
Business Development & Partnerships

Catalent, Lisata partner on ADC development using certepetide tumor drug, $10M milestone deal
Research collaboration, oncology, antibody-drug conjugate, milestone payments - Read more

AviadoBio, UgeneX Therapeutics secure option deal for rare eye disease gene therapy worth up to $413M
Licensing deal, rare disease, gene therapy, milestone payments - Read more

Santhera, Biomedica partner for exclusive AGAMREE distribution in Russia for DMD patients, sales starting Q1 2026
Distribution agreement, rare disease, neurological, royalties - Read more

AstraZeneca, Turbine partner to accelerate ADC discovery using AI-powered virtual lab platform
Research collaboration, oncology, AI/ML, antibody-drug conjugate, drug discovery - Read more

PRESENTED BY YOU?
Get the attention of 2200+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

Ono Pharmaceutical’s, Bristol Myers Squibb's ONO-4578 EP4 antagonist meets Ph2 progression-free survival endpoint in gastric cancer patients
Small molecule, cancer, EP4 antagonist, gastric cancer, combination therapy, PD-1 inhibitor - Read more

Orexa reports positive Ph2 results for ORE-001 in post-operative ileus prevention following abdominal surgery
Small molecule, gastrointestinal, post-operative ileus, gynecologic surgery, phase 2 trial - Read more

Ono Pharmaceuticals reports positive Ph2 interim results for ONO-2808 S1P5 receptor agonist in multiple system atrophy
Small molecule, neurological, S1P5 receptor agonist, multiple system atrophy, Phase 2 trial - Read more

Genethon reports positive 2-year Ph3 data for GNT0004 micro-dystrophin gene therapy in Duchenne muscular dystrophy
Gene therapy, neurological, adeno-associated virus, Duchenne muscular dystrophy, micro-dystrophin, rare disease - Read more

Henlius' Hetronifly (PD-1 inhibitor) meets primary endpoint in Ph3 gastric cancer trial, enabling NDA submission
Antibody, cancer, PD-1 inhibitor, gastric cancer, combination therapy, neoadjuvant - Read more

ABLi Therapeutics' Risvodetinib meets Ph2 safety endpoint for c-Abl kinase inhibition in Parkinson's disease treatment
Small molecule, neurological, kinase inhibitor, Parkinson's disease, c-Abl kinase - Read more

University of Eastern Finland reports successful Ph2b results for VEGF-D gene therapy in refractory angina patients
Gene therapy, cardiovascular, adenoviral vector, refractory angina, VEGF-D - Read more

THE GOOD
Fundraises

Ascenta raises $325M inaugural fund, ex-Moderna leaders backing platform biotechs
Venture capital, platform technology, clinical-stage, multi-indication - Read more

Expedition Therapeutics raises $165M Series A, DPP1 inhibitor for COPD treatment
COPD, small molecule, inflammatory diseases, clinical-stage - Read more

Apogee Therapeutics raises $300M public offering, clinical-stage inflammatory/immunology biologics
Clinical-stage, antibody, inflammatory disease, autoimmune - Read more

Chengdu New Radiomedicine raises $117M Series D, “scarce” nuclides and radiopharmaceuticals production
Radiopharmaceuticals, oncology, clinical-stage, platform technology - Read more [Press release in Chinese]

THE GOOD
Investments

Lupin invests $250M to build Florida respiratory drug manufacturing plant, creating 200+ jobs
Respiratory drugs, respiratory disease, operational, strategic, major transaction - Read more

AstraZeneca begins construction of $4.5B Virginia API manufacturing facility for weight management and ADC drugs
Antibody-drug conjugate, metabolic disease, strategic, major transaction, operational - Read more

THE GOOD
Mergers & Acquisitions

Novo Nordisk acquires Akero Therapeutics for $4.7B to expand MASH liver disease treatment portfolio
FGF21 agonist, metabolic liver disease, strategic, major transaction - Read more

THE GOOD
Regulatory

FDA breakthrough therapy designation leads to 72% drug approval rate, Jefferies report shows
Regulatory, oncology, strategic, operational - Read more

MHRA and FDA strengthen partnership to fast-track AI and medical device approvals globally
Medical devices, regulatory, strategic, international collaboration - Read more

THE GOOD
Politics & Policy

GoodRx explores partnership with Trump's direct-to-consumer drug platform TrumpRx launching next year
Direct-to-consumer platform, multiple therapeutic areas, strategic, regulatory, competitive, major transaction - Read more

THE BAD
Approvals & Labels

FDA rejects Xspray's dasynoc approval bid for chronic myeloid leukemia over manufacturing concerns
Small molecule, cancer, chronic myeloid leukemia, acute lymphoblastic leukemia, manufacturing issues - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here